|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GHITM |
Gene summary for GHITM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GHITM | Gene ID | 27069 |
| Gene name | growth hormone inducible transmembrane protein | |
| Gene Alias | DERP2 | |
| Cytomap | 10q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0001836 | UniProtAcc | Q9H3K2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27069 | GHITM | LN38 | Human | Oral cavity | OSCC | 5.11e-16 | 2.65e+00 | 0.168 |
| 27069 | GHITM | LN46 | Human | Oral cavity | OSCC | 1.62e-24 | 1.35e+00 | 0.1666 |
| 27069 | GHITM | LP15 | Human | Oral cavity | LP | 8.32e-16 | 2.16e+00 | 0.2174 |
| 27069 | GHITM | LP17 | Human | Oral cavity | LP | 1.93e-07 | 1.35e+00 | 0.2349 |
| 27069 | GHITM | SYSMH1 | Human | Oral cavity | OSCC | 1.07e-42 | 1.14e+00 | 0.1127 |
| 27069 | GHITM | SYSMH2 | Human | Oral cavity | OSCC | 3.50e-33 | 1.45e+00 | 0.2326 |
| 27069 | GHITM | SYSMH3 | Human | Oral cavity | OSCC | 9.07e-32 | 1.36e+00 | 0.2442 |
| 27069 | GHITM | SYSMH4 | Human | Oral cavity | OSCC | 8.19e-08 | 2.35e-01 | 0.1226 |
| 27069 | GHITM | SYSMH5 | Human | Oral cavity | OSCC | 2.55e-05 | 3.81e-01 | 0.0647 |
| 27069 | GHITM | SYSMH6 | Human | Oral cavity | OSCC | 2.35e-17 | 8.72e-01 | 0.1275 |
| 27069 | GHITM | P4_S8_cSCC | Human | Skin | cSCC | 1.05e-10 | 2.23e-02 | -0.3095 |
| 27069 | GHITM | P5_S10_cSCC | Human | Skin | cSCC | 2.32e-10 | -1.04e-01 | -0.299 |
| 27069 | GHITM | P1_cSCC | Human | Skin | cSCC | 1.57e-42 | 1.65e+00 | 0.0292 |
| 27069 | GHITM | P2_cSCC | Human | Skin | cSCC | 3.92e-41 | 1.10e+00 | -0.024 |
| 27069 | GHITM | P4_cSCC | Human | Skin | cSCC | 8.67e-56 | 1.47e+00 | -0.00290000000000005 |
| 27069 | GHITM | P10_cSCC | Human | Skin | cSCC | 7.32e-52 | 1.78e+00 | 0.1017 |
| 27069 | GHITM | cSCC_p4 | Human | Skin | cSCC | 3.30e-05 | -6.11e-03 | -0.2022 |
| 27069 | GHITM | cSCC_p7 | Human | Skin | cSCC | 1.78e-03 | -2.45e-01 | -0.2332 |
| 27069 | GHITM | cSCC_p8 | Human | Skin | cSCC | 8.86e-14 | 1.67e-01 | -0.1971 |
| 27069 | GHITM | cSCC_p9 | Human | Skin | cSCC | 3.61e-11 | 1.50e-01 | -0.1991 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0046034 | Colorectum | AD | ATP metabolic process | 142/3918 | 277/18723 | 2.64e-29 | 8.26e-26 | 142 |
| GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
| GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
| GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
| GO:0006119 | Colorectum | AD | oxidative phosphorylation | 83/3918 | 141/18723 | 7.95e-23 | 8.30e-20 | 83 |
| GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
| GO:0022900 | Colorectum | AD | electron transport chain | 89/3918 | 175/18723 | 1.42e-18 | 8.91e-16 | 89 |
| GO:0042773 | Colorectum | AD | ATP synthesis coupled electron transport | 56/3918 | 95/18723 | 6.76e-16 | 2.22e-13 | 56 |
| GO:0042775 | Colorectum | AD | mitochondrial ATP synthesis coupled electron transport | 56/3918 | 95/18723 | 6.76e-16 | 2.22e-13 | 56 |
| GO:0022904 | Colorectum | AD | respiratory electron transport chain | 63/3918 | 114/18723 | 8.23e-16 | 2.45e-13 | 63 |
| GO:2001233 | Colorectum | AD | regulation of apoptotic signaling pathway | 119/3918 | 356/18723 | 2.14e-08 | 1.21e-06 | 119 |
| GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
| GO:0010821 | Colorectum | AD | regulation of mitochondrion organization | 57/3918 | 144/18723 | 2.43e-07 | 9.92e-06 | 57 |
| GO:0007006 | Colorectum | AD | mitochondrial membrane organization | 48/3918 | 116/18723 | 4.53e-07 | 1.72e-05 | 48 |
| GO:0043467 | Colorectum | AD | regulation of generation of precursor metabolites and energy | 49/3918 | 130/18723 | 8.33e-06 | 1.99e-04 | 49 |
| GO:0008637 | Colorectum | AD | apoptotic mitochondrial changes | 42/3918 | 107/18723 | 1.13e-05 | 2.56e-04 | 42 |
| GO:2001234 | Colorectum | AD | negative regulation of apoptotic signaling pathway | 74/3918 | 224/18723 | 1.49e-05 | 3.18e-04 | 74 |
| GO:0001836 | Colorectum | AD | release of cytochrome c from mitochondria | 25/3918 | 59/18723 | 1.58e-04 | 2.20e-03 | 25 |
| GO:0007007 | Colorectum | AD | inner mitochondrial membrane organization | 18/3918 | 38/18723 | 2.45e-04 | 3.09e-03 | 18 |
| GO:0090199 | Colorectum | AD | regulation of release of cytochrome c from mitochondria | 18/3918 | 48/18723 | 6.21e-03 | 3.88e-02 | 18 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GHITM | SNV | Missense_Mutation | c.440N>A | p.Arg147Lys | p.R147K | Q9H3K2 | protein_coding | deleterious(0.04) | probably_damaging(0.932) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| GHITM | SNV | Missense_Mutation | c.212N>C | p.Met71Thr | p.M71T | Q9H3K2 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| GHITM | SNV | Missense_Mutation | rs758527392 | c.164N>A | p.Arg55His | p.R55H | Q9H3K2 | protein_coding | tolerated(0.08) | possibly_damaging(0.861) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GHITM | deletion | Frame_Shift_Del | novel | c.635delG | p.Gly212ValfsTer31 | p.G212Vfs*31 | Q9H3K2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| GHITM | SNV | Missense_Mutation | rs572795538 | c.902G>A | p.Arg301His | p.R301H | Q9H3K2 | protein_coding | tolerated(0.17) | benign(0.019) | TCGA-A6-2684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| GHITM | SNV | Missense_Mutation | rs111408234 | c.1008G>A | p.Met336Ile | p.M336I | Q9H3K2 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-A01S-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GHITM | SNV | Missense_Mutation | novel | c.850N>G | p.Leu284Val | p.L284V | Q9H3K2 | protein_coding | deleterious(0.01) | possibly_damaging(0.789) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| GHITM | SNV | Missense_Mutation | c.596N>C | p.Val199Ala | p.V199A | Q9H3K2 | protein_coding | tolerated(0.09) | benign(0.326) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GHITM | SNV | Missense_Mutation | c.707N>T | p.Ala236Val | p.A236V | Q9H3K2 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GHITM | SNV | Missense_Mutation | novel | c.856C>A | p.Leu286Ile | p.L286I | Q9H3K2 | protein_coding | deleterious(0) | possibly_damaging(0.732) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |